Pharmaceutical Industry

With an increasing number of drugs that are ineligible for reimbursement, companies have to better demonstrate their product's value. (Image: iStock/VladimirFLoyd)

Exclusion lists challenging drug developers

By Melissa Fassbender

Rising drug prices and the subsequent increasing number of drugs ineligible for reimbursement will challenge drug developers to provide clinical superiority evidence.